Rocket Pharmaceuticals(RCKT)2025-05-08 20:12Financial Performance - As of March 31, 2025, Rocket Pharmaceuticals had cash, cash equivalents, and investments totaling approximately 35.9 million, a decrease of 45.2 million in Q1 2024, primarily due to reduced manufacturing and development costs[11]. - General and administrative expenses increased to 22.1 million in Q1 2024, driven by higher legal expenses and commercial preparation costs[11]. - The net loss for Q1 2025 was 0.56 per share, compared to a net loss of 0.66 per share, in Q1 2024[11]. - The total operating expenses for Q1 2025 were 67.4 million in Q1 2024[15]. Clinical Development - The ongoing Phase 2 pivotal study of RP-A501 for Danon disease is expected to provide a program update in mid-2025, with clinical data readout anticipated in mid-2026[4]. - Initial data from the Phase 1 study of RP-A601 for PKP2-ACM is expected in May 2025, with an estimated 50,000 people affected in the U.S. and Europe[6]. - The company is on track to submit an IND for the BAG3-DCM program in mid-2025[3]. - Rocket Pharmaceuticals is progressing with the rolling Biologics License Application (BLA) for RP-L102 for Fanconi Anemia, with final module submission anticipated in late 2025 or early 2026[6]. Leadership Changes - The company appointed Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer in April 2025[5].